Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CIGNA's Limited Brand Coverage In Part D Gap Emphasizes Challenges

Executive Summary

After several years of no national Medicare Part D prescription drug plan sponsors offering any kind of brand drug coverage in the donut hole, CIGNA's "Medicare Rx Plan Three" product offering in 2010 will give seniors suffering from hypothyroidism that option

You may also be interested in...



CMS Budgets $110 Million For Broad Internal IT System Overhaul

CMS is planning a broad initiative aimed at making the wealth of data it collects from Medicare and Medicaid beneficiaries more accessible and usable for analysis and is asking Congress for $110 million to accomplish it

CMS Budgets $110 Million For Broad Internal IT System Overhaul

CMS is planning a broad initiative aimed at making the wealth of data it collects from Medicare and Medicaid beneficiaries more accessible and usable for analysis and is asking Congress for $110 million to accomplish it

Getting To $80 Bil.: PhRMA Expects Mix Of Rebates And Fees In Finance Bill

The Pharmaceutical Research and Manufacturers of America is expecting to make good on its pledge to contribute $80 billion to health care reform through a combination of drug rebates and fees, in addition to savings from follow-on biologics and the previously announced 50 percent discount on drugs used in the Medicare Part D donut hole

Related Content

Topics

UsernamePublicRestriction

Register

PS051555

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel